According to the WiseNews app, Beigene (06160) rose nearly 3% intraday, as of the time of publication, it rose by 2.29%, closing at 120.5 Hong Kong dollars, with a turnover of 0.14 billion Hong Kong dollars.

On the news front, on November 19, according to the CDE website, Beigene's application for the Type 1 new drug BGB-58067 tablets has been granted clinical trial implicit permission, intended to develop treatments for late-stage solid tumor patients. According to public information from Beigene, BGB-58067 is a PRMT5 inhibitor and one of Beigene's future core projects. According to the CDE official website query, this is the first time this product has been clinically approved in China.

Bocom Intl released a research report pointing out that based on 3Q performance and a continued strong trend in product volume, revenue forecasts for 2024-2026 have been raised by 6-7%, while peak sales forecasts for zebutinib have been raised by 4% to 5.4 billion. The firm stated that over the next 12 months, the focus will be on: 1) approvals for more indications in core developed countries such as Orelis zinc LESC, 1LGC, etc., and data readouts for combination I/O therapies (Orelis plus OX40, LAG3, etc.); 2) initiation of two Phase III studies for the Bcl-2 inhibitor sonrutocax 1H25 (R/RCLL and R/RMCL) with preliminary data readouts for more indications; 3) initiation of the first Phase III clinical trial for the BTK degrader 1H25 (R/RCLL); 4) entry of more candidate drug molecules for solid tumors into clinical stages: 8 have entered clinical trials this year, with an expected additional 4 by the end of the year.